GT Biopharma Names Dr. Jeff Miller as Consulting Chief Medical Officer
14 déc. 2022 07h30 HE
|
GT Biopharma, Inc.
BRISBANE, CALIFORNIA, Dec. 14, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative...
GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022
12 déc. 2022 07h30 HE
|
GT Biopharma, Inc.
Presentation shows the therapeutic potential of combining iPSC-derived CAR NK cells and NK cell engagers to overcome the clinical heterogeneity of AML BRISBANE, CALIFORNIA, Dec. 12, 2022 (GLOBE...
GT Biopharma Presents Two Posters at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
10 nov. 2022 15h15 HE
|
GT Biopharma, Inc.
Poster #1: Tri-specific killer engagers target natural killer cells towards mesotheliomaPoster #2: Enhancing NK cell function in the 'cold' tumor microenvironment of prostate cancer with a novel...
GT Biopharma to Present New Data on Novel Dual-Antigen Targeting Approach Against AML at Upcoming 2022 ASH Annual Meeting
03 nov. 2022 09h00 HE
|
GT Biopharma, Inc.
BRISBANE, CALIFORNIA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative...
GT Biopharma Reports Third Quarter Fiscal 2022 Financial Results and Business Update
31 oct. 2022 17h15 HE
|
GT Biopharma, Inc.
Announced two poster presentations at the Society for Immunotherapy of Cancer’s 37th Annual Meeting (SITC 2022)$20.8 million in cash, cash equivalents and short-term investments as of September 30,...
GT Biopharma Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
06 oct. 2022 08h18 HE
|
GT Biopharma, Inc.
BRISBANE, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics...
GT Biopharma Announces Adjournment of Special Shareholders Meeting
04 oct. 2022 16h10 HE
|
GT Biopharma, Inc.
- Meeting adjourned to October 10, 2022 at 11 a.m. PST- GTB encourages all stockholders of record on August 8, 2022 who have not yet voted- to do so by 11:59 p.m. PST Time on October 9, 2022 ...
GT Biopharma Poster Presentation and Mini Oral Session at ESMO Congress 2022 Demonstrates GTB-5550 TriKE® Ability to Specifically Target and Efficiently Kill Multiple B7H3+ Solid and Hematologic Malignancies
12 sept. 2022 09h34 HE
|
GT Biopharma, Inc.
GTB-5550 generates a robust and NK cell specific proliferation signal compared to IL-15 aloneGTB-5550 specifically targets B7-H3+ cellsGTB-5550 effectively induced NK cell degranulation and interferon...
GT Biopharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference in September
08 sept. 2022 07h30 HE
|
GT Biopharma, Inc.
BRISBANE, Calif., Sept. 08, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's...
GT Biopharma Affirms Manufacturing Timeline For Lead Investigational Asset GTB-3650
30 août 2022 18h00 HE
|
GT Biopharma, Inc.
GTB-3650’s IND application with the FDA expected by end of first quarter of 2023 BRISBANE, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a...